Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2024-05-02 Director's Dealing
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Gentian Diagnostics: Mandatory notificaton of trade
Director's Dealing Classification · 100% confidence The document explicitly states it is a "Mandatory notificaton of trade" concerning a primary insider (Fredrik Thoresen) and his close associate (Kvantia AS) buying shares. This directly corresponds to the definition of Director's Dealing (insider trades). Filing Category: Director's Dealing (Code: DIRS).
2024-05-02 English
Gentian Diagnostics: First quarter 2024 report
Investor Presentation Classification · 99% confidence The document is explicitly titled "Q1 24 Presentation" and contains detailed financial highlights for the first quarter of 2024 (1Q24), including sales figures, gross margin, EBITDA, balance sheet data, and product updates. This structure—a presentation format summarizing recent quarterly performance—is characteristic of an Investor Presentation (IP). It is not a full Annual Report (10-K), nor is it a brief Earnings Release (ER) announcing results; it is a comprehensive presentation deck used for investor communication regarding interim results.
2024-04-30 English
Gentian Diagnostics: First quarter 2024 report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly report for Gentian Diagnostics for the first quarter of 2024. It contains detailed financial performance data (sales, EBITDA, gross margins), operational summaries, market development updates, product development progress, and a long-term outlook. It is not a short announcement or a press release, but a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2024
2024-04-30 English
Gentian Diagnostics: First quarter 2024 report
Earnings Release Classification · 100% confidence The document explicitly states it is the 'First quarter 2024 report' and provides key financial highlights (sales, EBITDA, gross margin) for that period. This structure—a brief announcement summarizing key figures for a recent fiscal period shorter than a year—is characteristic of an Earnings Release (ER). It is not the comprehensive report itself (which would be an IR), nor is it a transcript (CT) or a presentation (IP). The length (2444 chars) confirms it is a summary announcement. Q1 2024
2024-04-30 English
Gentian Diagnostics: New acting CEO and Chairperson of the Board of Directors
Board/Management Information Classification · 100% confidence The document explicitly announces changes in senior leadership: the appointment of Mr. Njaal Kind as acting CEO and the election of Ms. Hilja Ibert as chairperson of the board of directors, leading to her resignation as CEO. This directly matches the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-04-29 English
Gentian Diagnostics: Minutes from Annual General Meeting
AGM Information Classification · 100% confidence The document text is explicitly titled 'PROTOKOLL FRA ORDINÆR GENERALFORSAMLING' (Minutes of Annual General Meeting) and details the proceedings, resolutions, and voting results from a meeting held on April 29, 2024. Key agenda items include the approval of the annual financial statements, remuneration reports, election of board members, and authorizations for capital increases. This content directly corresponds to the documentation generated following an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2024-04-29 Norwegian

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.